Acadia Pharmaceuticals | ACAD

Stock Price
25.26
Daily Change
-0.24 -0.94%
Monthly
6.13%
Yearly
57.19%
Q3 Forecast
25.05

Peers Price Chg Day Year Date
Eisai 5,137.00 125.00 2.49% -11.57% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Prothena 8.55 0.34 4.14% -57.94% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Acadia Pharmaceuticals traded at $25.26 this Friday September 5th, decreasing $0.24 or 0.94 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals lost 6.13 percent. Over the last 12 months, its price rose by 57.19 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 25.05 by the end of this quarter and at 24.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).